

Meeting Minutes
Incontinence in Neurological Disease - GDG Meeting 8
Location: National Clinical Guidelines Centre - Boardroom
24th June, 2011

GDG		NCGC	
Alun Williams	AW	Dave Wonderling	DW
Amelia Denny	AD	Gill Ritchie	GR
Christine Anderson	CA	Mark Perry	MP
Clare Fowler	CF	Ralph Hughes	RH
Judith Jesky	JJ	Sharon Swain	SS
Julie Vickerman	JV	Tamara Diaz	TD
Keith MacDermott	KM		
Laura Graham	LGr	Apologies	
Noreen Barker	NB	Susie Orme	SO
Paul Tophill	PT	Doreen Mc Clurg	DM
Simon Harrison (Chair)	SH	Alison Bardsley	AB
Sue Woodward	SW		
		NICE Observer	
		Sarah Dunsdon	SD
		Clifford Middleton	CM

1. Welcome and Apologies

1.1. The Chair (SH) welcomed attendees to the Incontinence in Neurological Disease (IND) guideline development group (GDG) meeting 8 and apologies were heard for: GDG members Susie Orme, Doreen Mc Clurg and Alison Bardsley. Observers of the day's meeting included: Sarah Dunsdon and Clifford Middleton who will be replacing Sarah as Guidelines Commissioning Managers for the IND Guideline.

2. Declarations of Interest

- 2.1. The following personal non-pecuniary interests were declared to the group:
- 2.1.1. **SH** - attended evening symposium at British Association of Urological Surgeons Annual meeting on 21/06/2011 – sponsored by Pfizer.
 - 2.1.2. **PT** - attended an evening meeting on 21/06/2011 sponsored by Pfizer and accommodation on 20 – 21/06/2011 was sponsored by Astellas.
 - 2.1.3. **JV** – Chairmanship of the Association for Continence Advice (ACA) the North West Association for Continence Advice (ACA) education meeting was sponsored by Astellas.
- 2.2. There were no further declarations of interest relevant to the day's agenda.
Action: TD: Follow up with PT and SH for written DOI reports.

3. Minutes of GDG 7

The Minutes of GDG 7 were reviewed and agreed by the GDG. There were no matters arising from the minutes of GDG 7.

4. The Chair presented an overview of the agenda.

5. Economic Model: Botulinum Toxin vs Augmentation Cystoplasty

5.1. **RH** presented the economic model to the group. The model compared the cost effectiveness of two methods for the treatment and prevention of incontinence in neurological disease: augmentation cystoplasty and the injection of Botulinum toxin (BTX) in the bladder wall.

6. Review of Clinical and Health Economic Evidence:

6.1. What is the safety and efficacy of the catheter valve compared with urinary drainage bags in neurological disease?

6.1.1. Introduction: Catheter Valves

SH provided an introduction to catheter valves. This introduction covered the type of catheters and valves used and the storage systems available for urinary waste. The pros and cons of using this equipment were discussed, along with the impact on patients' quality of life and suitability for catheter valve use.

6.1.2. Clinical Evidence:

No randomised controlled trials (RCTs) or observational studies were identified comparing catheter valves with urinary drainage bags for improving outcomes in patients with neurological disease or injury.

6.2. What is the safety and efficacy of urethral tape and sling surgery compared with a) bladder neck closure b) usual care in neurological disease?

6.2.1. Introduction: Urethral tape and sling surgery

SH delivered a presentation that introduced the group to the surgical procedures involved in urethral tape and sling surgery, and AW delivered an introductory presentation on considerations for the paediatric population for this surgical procedure.

6.2.2. Clinical Evidence: 23 observational studies were included in the review.

Three observational studies focussed on tape surgery and 20 looked at sling surgery. No studies were identified comparing urethral tape or sling surgery with bladder neck closure. The evidence was presented according to whether the population was adults, children, or a mixed population. It was further sub-grouped into whether or not bladder augmentation was performed before or at the same time as the tape and sling surgery.

7. Any other business and close of meeting

7.1. There being no further business the meeting ended at 3:30 p.m.

The next GDG meeting will be held on 29th July, 2011 from 10:30 – 16:30 and take place at the NCGC's offices located at 180 Great Portland Street, London, W1W 5QZ.